Company news
Cumberland Pharmaceuticals Inc. news in 2025
Cumberland Pharmaceuticals Inc.'s news releases, calls and decks from 2025, newest first.
Caldolor® (ibuprofen) injection cms issued J-Code now associated with reimbursement price supporting non-opioid pain management
December 8, 2025
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
December 1, 2025
Cumberland Pharmaceuticals reports 12% year-to-date revenue growth
November 4, 2025
Cumberland Pharmaceuticals to announce Q3 2025 financial results & company update
October 28, 2025
RedHill Biopharma Receives Nasdaq Staff Determination Notification
October 22, 2025
Cumberland phamaceuticals announces the addition of an established FDA approved product to its commercial portfolio
October 20, 2025
Cumberland Pharmaceuticals' Vibativ® added to national group purchasing agreement with Premier, inc.
October 13, 2025
Cumberland Pharmaceuticals announces product approval in Mexico
October 1, 2025
Tabuk launches Vibativ® FDA-approved antibiotic with life-saving potential in Saudi Arabia
September 29, 2025
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
August 5, 2025
Cumberland Pharmaceuticals receives Vizient contract for new Vibativ® 4-Vial Starter Pak
August 4, 2025
Cumberland Pharmaceuticals to announce Q2 2025 financial results & company update
July 29, 2025
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
June 23, 2025
New study finds Caldolor® safe and effective for opioid-sparing pain management in older adults
May 27, 2025
Cumberland Pharmaceuticals partners with Qureight to advance innovative idiopathic pulmonary fibrosis treatment research
May 13, 2025
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
May 6, 2025
Cumberland Pharmaceuticals to announce Q1 2025 financial results & company update
April 29, 2025
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
March 19, 2025
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
March 4, 2025
Cumberland Pharmaceuticals to announce annual 2024 financial results
February 25, 2025
Vibativ® receives marketing approval in China
February 18, 2025
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
February 3, 2025
Calls in 2025
- Cumberland Pharmaceuticals (NASDAQ:CPIX) Q3 2025 Earnings Call
Nov 4, 2025
Transcript - Cumberland Pharmaceuticals (NASDAQ:CPIX) Q2 2025 Earnings Call
Aug 5, 2025
Transcript - Cumberland Pharmaceuticals (NASDAQ:CPIX) Q1 2025 Earnings Call
May 6, 2025
Transcript - Cumberland Pharmaceuticals (NASDAQ:CPIX) Q4 2024 Earnings Call
Mar 4, 2025
Transcript